EYPT

EyePoint Pharmaceuticals, Inc. [EYPT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EYPT Stock Summary

Top EYPT Correlated Resources

EYPT


Top 10 Correlated ETFs

EYPT


Top 10 Correlated Stocks

EYPT


In the News

08:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

07:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments.

01:33 22 Mar 2023 EYPT

5 Penny Stocks To Buy According To Analysts, Targets Up To 992%

Analysts say these are penny stocks to buy. Do you agree?

08:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

01:58 22 Mar 2023 EYPT

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:13 AM ET EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q3 2022 Earnings Conference Call November 02, 2022, 08:30 AM ET Company Participants Nancy Lurker - President and CEO George Elston - CFO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen Yi Chen - H.C. Wainwright Yale Jen - Laidlaw & Company Daniil Gatualin - Chardan Yuan Zhi - B.

09:48 22 Mar 2023 EYPT

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

07:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments.

04:01 22 Mar 2023 EYPT

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

12:17 22 Mar 2023 EYPT

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Shares have lost 15% year to date. Durasert technology has been extensively validated and administered to over 80,000 patient eyes.

03:05 22 Mar 2023 EYPT

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and Chief Executive Officer Jay Duker - Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Jennifer Kim - Cantor Yale Jen - Laidlaw Yi Chen - H.C. Wainwright Operator Good morning.

EYPT Financial details

Company Rating
Neutral
Market Cap
80.09M
Income
-102.25M
Revenue
41.4M
Book val./share
2.58
Cash/share
3.87
Dividend
-
Dividend %
-
Employees
122
Optionable
No
Shortable
Yes
Earnings
02 May 2023
P/E
-1.21
Forward P/E
-
PEG
0.3
P/S
2.24
P/B
0.7
P/C
0.66
P/FCF
-1.24
Quick Ratio
5.2
Current Ratio
5.61
Debt / Equity
0.87
LT Debt / Equity
0.37
-
-
EPS (TTM)
-2.73
EPS next Y
-
EPS next Q
-0.56
EPS this Y
-39.79%
EPS next Y
-
EPS next 5Y
-37.18%
EPS last 5Y
-24.94%
Revenue last 5Y
69.48%
Revenue Q/Q
5.2%
EPS Q/Q
136.73%
-
-
-
-
SMA20
-50%
SMA50
-33.33%
SMA100
-66.67%
Inst Own
78.66%
Inst Trans
-1.95%
ROA
-35%
ROE
-49%
ROC
-0.4%
Gross Margin
81%
Oper. Margin
-174%
Profit Margin
-184%
Payout
-
Shs Outstand
34.3M
Shs Float
18.09M
-
-
-
-
Target Price
25
52W Range
2.19-13.63
52W High
-80.42%
52W Low
+27.25%
RSI
38
Rel Volume
0.65
Avg Volume
284.51K
Volume
185.81K
Perf Week
-0.97%
Perf Month
-43.94%
Perf Quarter
-66.73%
Perf Half Y
-67.29%
-
-
-
-
Beta
1.03963
-
-
Volatility
0.08%, 0.59%
Prev Close
0%
Price
2.545
Change
2.21%

EYPT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-06-302019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.641.952.682.881.11
Net income per share
-11.5-5.44-3.54-4.55-2.74
Operating cash flow per share
-4.74-5.44-1.12-3.9-1.74
Free cash flow per share
-4.76-5.46-1.15-3.92-1.8
Cash per share
8.392.133.516.483.87
Book value per share
2.530.81.4414.362.58
Tangible book value per share
-4.26-1.85-0.5212.592.58
Share holders equity per share
2.530.81.4414.362.58
Interest debt per share
3.95.443.713.481.31
Market cap
96.15M161.68M84.46M157.11M130.61M
Enterprise value
74.68M190.06M79.86M17.72M80.75M
P/E ratio
-1.81-2.85-1.86-2.69-1.28
Price to sales ratio
32.477.942.454.253.15
POCF ratio
-4.39-2.85-5.85-3.14-2.01
PFCF ratio
-4.37-2.84-5.71-3.13-1.94
P/B Ratio
8.2319.414.560.851.36
PTB ratio
8.2319.414.560.851.36
EV to sales
25.229.332.320.481.95
Enterprise value over EBITDA
-1.46-3.96-2.25-0.35-0.83
EV to operating cash flow
-3.41-3.35-5.53-0.35-1.24
EV to free cash flow
-3.39-3.34-5.4-0.35-1.2
Earnings yield
-0.55-0.35-0.54-0.37-0.78
Free cash flow yield
-0.23-0.35-0.18-0.32-0.51
Debt to equity
5.137.763.950.430.87
Debt to assets
0.840.890.80.30.47
Net debt to EBITDA
0.42-0.590.132.780.51
Current ratio
1.843.624.2410.055
Interest coverage
-36.49-7.75-5.14-10.05-31.24
Income quality
0.4110.320.860.64
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.90.880.60.690.84
Research and developement to revenue
5.460.750.510.771.2
Intangibles to total assets
0.440.380.270.090
Capex to operating cash flow
000.0300.03
Capex to revenue
-0.04-0.01-0.010-0.05
Capex to depreciation
-0.09-0.08-0.14-0.06-1.05
Stock based compensation to revenue
0.910.220.160.20.34
Graham number
25.589.8910.7238.3512.62
ROIC
2.98-1.9712.810.555.92
Return on tangible assets
-1.32-1.25-0.68-0.24-0.57
Graham Net
-4.53-3.15-1.4411.541.97
Working capital
18.25M30.2M48.23M214.09M138.27M
Tangible asset value
-19.67M-19.34M-6.67M161.63M96.37M
Net current asset value
-20.07M-22.92M-10.06M158.75M88.82M
Invested capital
1.486.072.170.210.47
Average receivables
302K5.86M10.41M13.9M16.93M
Average payables
1.98M3.57M4.5M6.1M6.65M
Average inventory
01.07M3.74M4.48M3.25M
Days sales outstanding
43.51203.75100.19181.36136.67
Days payables outstanding
0569.44301.51329.65259.48
Days of inventory on hand
0290.42334.48161.41126.52
Receivables turnover
8.391.793.642.012.67
Payables turnover
00.641.211.111.41
Inventory turnover
01.261.092.262.88
ROE
-4.55-6.82-2.45-0.32-1.06
Capex per share
-0.02-0.02-0.03-0.01-0.06

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
0.350.250.310.270.28
Net income per share
-0.59-0.56-0.52-0.49-1.16
Operating cash flow per share
-0.51-0.54-0.51-0.35-0.34
Free cash flow per share
-0.51-0.55-0.52-0.38-0.35
Cash per share
6.475.124.594.213.87
Book value per share
5.644.484.063.652.58
Tangible book value per share
4.943.883.483.092.58
Share holders equity per share
5.644.484.063.652.58
Interest debt per share
1.241.141.211.261.25
Market cap
400.25M452.62M293.72M295.34M130.61M
Enterprise value
260.86M392.36M256.07M266.44M80.75M
P/E ratio
-5.15-5.39-3.78-4.01-0.75
Price to sales ratio
34.6748.725.429.512.4
POCF ratio
-24.01-22.45-15.36-22.48-10.38
PFCF ratio
-24.01-22.29-15.19-20.6-9.91
P/B Ratio
2.172.711.942.171.36
PTB ratio
2.172.711.942.171.36
EV to sales
22.642.2222.1426.617.67
Enterprise value over EBITDA
-15.04-20.56-14.11-15.63-1.89
EV to operating cash flow
-15.65-19.46-13.39-20.28-6.41
EV to free cash flow
-15.65-19.32-13.24-18.59-6.13
Earnings yield
-0.05-0.05-0.07-0.06-0.33
Free cash flow yield
-0.04-0.04-0.07-0.05-0.1
Debt to equity
0.430.470.540.620.87
Debt to assets
0.30.320.350.380.47
Net debt to EBITDA
8.043.162.071.71.17
Current ratio
10.056.876.175.615
Interest coverage
-13-15.31-34.81-27.79-56
Income quality
0.860.960.990.710.29
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.80.920.740.920.81
Research and developement to revenue
0.771.071.121.111.48
Intangibles to total assets
0.090.090.090.090
Capex to operating cash flow
00.010.010.090.05
Capex to revenue
0-0.02-0.02-0.12-0.06
Capex to depreciation
0-0.21-0.31-1.689.59
Stock based compensation to revenue
0.240.370.360.320.32
Graham number
8.687.536.896.378.23
ROIC
0.18-0.54-0.31-0.292.6
Return on tangible assets
-0.08-0.09-0.09-0.09-0.24
Graham Net
4.533.472.882.421.97
Working capital
214.09M187.66M172.48M157.85M138.27M
Tangible asset value
161.63M144.69M129.85M115.45M96.37M
Net current asset value
158.75M141.89M123.8M107.96M88.82M
Invested capital
0.210.250.290.340.47
Average receivables
15.98M18.97M21.09M21.74M18.19M
Average payables
7.01M7.34M7.18M6.59M6.02M
Average inventory
4.09M3.48M3.3M3.39M3.21M
Days sales outstanding
143.09189.69175.83187.66132.47
Days payables outstanding
219.14369.83366.33391.52156.22
Days of inventory on hand
107.3168.96168.89226.1976.17
Receivables turnover
0.630.470.510.480.68
Payables turnover
0.410.240.250.230.58
Inventory turnover
0.840.530.530.41.18
ROE
-0.11-0.13-0.13-0.14-0.45
Capex per share
00-0.01-0.03-0.02

EYPT Frequently Asked Questions

What is EyePoint Pharmaceuticals, Inc. stock symbol ?

EyePoint Pharmaceuticals, Inc. is a US stock , located in Watertown of Ma and trading under the symbol EYPT

Is EyePoint Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $25. The lowest prediction is $25 and the highest is $25

What is EYPT stock prediction ?

What is EyePoint Pharmaceuticals, Inc. stock quote today ?

EyePoint Pharmaceuticals, Inc. stock price is $2.545 today.

Is EyePoint Pharmaceuticals, Inc. stock public?

Yes, EyePoint Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap